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We report the molecular investigations of a large influ-
enza A(H3N2) outbreak, in a season characterised by 
sharp increase in influenza admissions since December 
2016. Analysis of haemagglutinin (HA) sequences 
demonstrated co-circulation of multiple clades (3C.3a, 
3C.2a and 3C.2a1). Most variants fell into a novel 
subclade (proposed as 3C.2a2); they possessed four 
unique amino acid substitutions in the HA protein and 
loss of a potential glycosylation site. These changes 
potentially modify the H3N2 strain antigenicity.
The ongoing influenza season started early in eleven 
European Union countries, including England, on week 
46 of 2016 [1]. The majority of reported infections 
have been caused by clade 3C.2a or 3C.2a1 influenza 
A(H3N2) viruses. The clade 3C.2a contains the current 
vaccine strain A/Hong Kong/4801/2014, and the first 
few viruses within the more recently emerged subclade 
3C.2a1 were earlier shown to be antigenically matched 
with the vaccine component [2]. However, evidence for 
suboptimal vaccine effectiveness (VE) against labora-
tory-confirmed influenza A infection in people over 65 
years-old was obtained in the first studies from Finland 
[3] and Sweden [4].
An outbreak of influenza A(H3N2) was first notified 
in our London centre on 30 December 2016. The out-
break coincided with unusually high ongoing circula-
tion of respiratory syncytial virus (RSV) (Figure 1), and 
affected both patients and staff in the acute medical 
unit (AMU).
While infection control precautions were intensified, it 
resulted in multiple bay closures. We suspected that 
the sharp increase in the number of influenza A(H3N2) 
infections may have been caused by the emergence 
of a new genetic variant of H3N2, a hypothesis inves-
tigated through next generation sequencing (NGS) of 
influenza A(H3N2) strains.
Collection and analysis of respiratory 
samples
The main study was based on respiratory samples 
(n = 1,690) analysed at the Department of Virology, 
University College of London Hospital (UCLH), United 
Kingdom between 21 December 2016 and 24 January 
2017. Most samples were collected as part of routine 
diagnostics from inpatients and patients seen at the 
Accident and Emergency department, and to a lesser 
extent from outpatients. The basic epidemiological 
data including patients’ age, admission and sampling 
dates as well as data on intensive care unit (ICU) 
admissions and deaths were collected. For comparison, 
results from influenza A and other virus testing from 
UCLH since 19 September 2016 were also analysed. The 
study was approved by the NRES Committee London, 
Surrey Borders HRA, (REC reference: 13/LO/1303).
All samples were initially screened for influenza A virus 
by reverse transcription-PCR targeting the matrix gene. 
A total of 67 influenza A(H3N2) virus-positive samples 
obtained between 8 December 2016 and 3 January 
2017 were sequenced. RNA was amplified using a 
modified eight-segment method [5]. Library prepara-
tions were generated as previously described [5,6]. A 
neighbour joining phylogenetic tree was constructed 
using Molecular Evolutionary Genetics Analysis (MEGA) 
6 software [7]. Some sequences in the phylogenetic 
analysis were from the Global Initiative on Sharing All 
Influenza Data (GISAID); the authors gratefully acknowl-
edge the 36 originating and submitting laboratories 
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who contributed sequences to GISAID (www.gisaid.
org). 
Characteristics of the influenza A(H3N2) 
outbreak
Of the 1,690 respiratory samples obtained between 
21 December 2016 and 24 January 2017, 352 samples 
were positive for influenza A(H3N2) virus (21%; Figure 
1). Of those, 294 influenza A(H3N2)-positive samples 
had been obtained from 253 UCLH patients. Of patients 
with influenza A(H3N2) infection, over 50% (128/253) 
required hospital admission. An average of three inpa-
tients (either existing inpatients or new admissions) 
were identified as influenza A(H3N2)-positive each 
day, and the highest number of hospital admissions 
was recorded on 10 January (n = 11; Figure 2a). Over the 
outbreak period, six patients required ICU admission 
and five died. Over a third of influenza A(H3N2) infec-
tions were seen in adults over 65 years-old (99/253; 
39%), most of them admitted to hospital (72/99; 73%, 
Figure 2b).
Description of influenza A(H3N2) viruses 
circulating in London
Phylogenetic analyses of haemagglutinin (HA) 
sequences indicated co-circulation of variants from 
subclades of 3C.3a (n = 2), 3C.2a1 (n = 31) and 3C.2a 
(n = 34) (Figure 3).
Interestingly, our 3C.2a virus strains differed from the 
previously characterised subclade 3C.2a strains as 
well as from subclade 3C.2a1, and hence we have pro-
posed them as a new subclade 3C.2a2. This subclade 
in turn split into two well defined but internally homog-
enous sub-clusters (cluster I and II; Figure 3), and also 
included all suspected outbreak cases admitted to 
AMU between 27 December 2016 and 3 January 2017 
(n = 15).
Figure 1
Percentage of positive respiratory samples for given viruses, and total number of respiratory samples tested per week, at 
the Department of Clinical Virology, University College of London Hospital, 19 September 2016–30 January 2017 (n=1,690 
samples)
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Individual clades of influenza A are typically defined 
by amino acid substitutions that occur as they diver-
sify from parental strains. Such substitutions are 
potentially functionally relevant as they may influence 
the antigenicity and susceptibility to neutralising anti-
body induced by infection with other lineages of H3N2. 
Thus, investigated variants within the subclades 3C.2a 
and 3C.2a1 (n = 65) inherited amino acid substitutions 
known to define their parental clades (Figure 4). All var-
iants within the proposed subclade 3C.2a2 shared two 
substitutions N121K and S144K, whereby S144K is an 
antigenic site flanking the receptor binding site (RBS). 
A further two additional substitutions were observed 
in each 3C.2a2 cluster (I58V and S219Y in cluster I and 
N122D and S262N in cluster II), all in the HA1 region 
and based on HA1 numbering. Cluster II viruses lost the 
potential N-linked glycosylation site (N122D).
Discussion
In our centre in London, the early start and higher 
intensity of the 2016/17 influenza A(H3N2) virus epi-
demic mirrored that of the season 2014/15 where the 
subtype H3N2 also predominated. During the 2014/15 
season, most influenza A(H3N2) infections in Europe 
were shown to be caused by antigenically drifted virus 
variants within the new genetic subgroup 3C.2a [8]. 
Our genetic analysis of London A(H3N2) viruses dem-
onstrates ongoing co-circulation of drifted variants 
from multiple subclades (3C.3a, 3C.2a1 and proposed 
3C.2a2). Four or more substitutions in two or more anti-
body binding sites are predicted to give an antigenically 
different virus [9] as in our case. Although we did not 
observe mutations in the seven positions suggested 
as being responsible for major transition clusters [10], 
position 144 is at the flank of the RBS, and additionally 
recognised as antigenic [11].
Figure 2
Number (A) and age distribution (B) of influenza A(H3N2)-positive patients diagnosed at the University College of London 
Hospitals, 16 December 2016–24 January 2017 (n=253 patients)
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Although not necessarily determining major antigenic 
drift, the alterations of N-linked glycosylation sites 
are likely to contribute to more complex conforma-
tional changes in the HA due to gain or loss of glyco-
sylation and can thus facilitate immune escape [12]. 
Furthermore, any amino acid changes in the 140–146 
region of HA have been shown to be characteristic for 
antigenically distinct viruses of epidemic significance 
[9,13,14]. The amino acid substitution S144K in the 
emerging subclade 3C.2a2 viruses together with the 
loss of an N-linked glycosylation site (N122D) shows 
potential for antigenic drift that warrants further moni-
toring during this ongoing season. A limitation of our 
study was the lack of detailed vaccination data.
Our findings in London of the rapid emergence of 
genetically drifted influenza A(H3N2) viruses under-
score the potential for such strains to spread rapidly 
in hospital environments among patients and staff. 
Characterising emerging strains of influenza by next 
generation sequencing adds to the local and national 
monitoring of influenza trends. Further studies are 
needed to investigate the antigenic effects of substi-
tutions occurring within the newly described subclade.
The ICONIC Consortium
Tiziano Gallo Cassarino, Myrto Kremyda-Vlachou, Ruth 
Blackburn, Catherine Smith, Duncan Clark, Steven Morris, 
Andrew Leigh-Brown, Anne Johnson.
Figure 3
Phylogenetic tree of the haemagglutinin gene sequences of virus strains recovered in this study using reference viruses for 
the different phylogenetic influenza A(H3N2)clades (n = 103 sequences)
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Bootstrap values obtained with 100 replicates are shown on some branches of the neighbour joining tree. The scale represents the percentage 
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London sequences retrieved in this study are indicated with coloured circles (n = 67), and the vaccine strain with a black circle.
The authors gratefully acknowledge the 36 originating and submitting laboratories who contributed sequences used in the phylogenetic 
analysis to the Global Initiative on Sharing All Influenza Data (GISAID; www.gisaid.org).
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Changes in HA1 are indicated in normal font while changes in HA2 
are in bold and italic. Changes in antigenic sites are shown with 
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